Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoru Muto

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Anticancer Research|March 14, 2007
FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograftTakanobu Ubai, Haruhito Azuma, Yatsugu Kotake, et al.
Hinyokika Kiyo. Acta Urologica Japonica|July 17, 2007
[A case of a giant adrenal myelolipoma in a man with spinal cord injury]Kojiro Nishio, Shino Tokiwa, Keisuke Saito, et al.
European Urology Open Science|August 2, 2021
The Use of Urine <i>Mycobacterium tuberculosis</i> Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non-muscle‑invasive Bladder CancerSatoru Muto, Yan Lu, Hisamitsu Ide, et al.
Plos One|January 28, 2020
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancerNaoya Nagaya, Masayoshi Nagata, Yan Lu, et al.
Human Molecular Genetics|July 4, 2002
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutantSatoru Muto, Atsu Aiba, Yuichirou Saito, et al.
Scientific Reports|May 29, 2023
Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastasesHisashi Hirano, Masayoshi Nagata, Naoya Nagaya, et al.
Journal of the American Society of Nephrology : JASN|January 21, 2026
Correction to: Kidney Week 2025 Abstract Three-Month Interim Analysis of Ketogenic Metabolic Therapy in Japanese Patients with ADPKD SA-PO0579Haruna Kawano, Wakana Koizumi, Yan Lu, et al.
Prostate Cancer and Prostatic Diseases|April 14, 2022
Gut environment changes due to androgen deprivation therapy in patients with prostate cancerAkimasa Kure, Tomoya Tsukimi, Chiharu Ishii, et al.
World Journal of Urology|June 28, 2018
Surveillance after prostate focal therapyKae Jack Tay, Mahul B Amin, Sangeet Ghai, et al.
Clinical and Experimental Nephrology|January 26, 2015
Novel prediction model of renal function after nephrectomy from automated renal volumetry with preoperative multidetector computed tomography (MDCT)Shuji Isotani, Hirofumi Shimoyama, Isao Yokota, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Anticancer Research|March 14, 2007
FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograftTakanobu Ubai, Haruhito Azuma, Yatsugu Kotake, et al.
Hinyokika Kiyo. Acta Urologica Japonica|July 17, 2007
[A case of a giant adrenal myelolipoma in a man with spinal cord injury]Kojiro Nishio, Shino Tokiwa, Keisuke Saito, et al.
European Urology Open Science|August 2, 2021
The Use of Urine <i>Mycobacterium tuberculosis</i> Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non-muscle‑invasive Bladder CancerSatoru Muto, Yan Lu, Hisamitsu Ide, et al.
Plos One|January 28, 2020
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancerNaoya Nagaya, Masayoshi Nagata, Yan Lu, et al.
Human Molecular Genetics|July 4, 2002
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutantSatoru Muto, Atsu Aiba, Yuichirou Saito, et al.
Scientific Reports|May 29, 2023
Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastasesHisashi Hirano, Masayoshi Nagata, Naoya Nagaya, et al.
Journal of the American Society of Nephrology : JASN|January 21, 2026
Correction to: Kidney Week 2025 Abstract Three-Month Interim Analysis of Ketogenic Metabolic Therapy in Japanese Patients with ADPKD SA-PO0579Haruna Kawano, Wakana Koizumi, Yan Lu, et al.
Prostate Cancer and Prostatic Diseases|April 14, 2022
Gut environment changes due to androgen deprivation therapy in patients with prostate cancerAkimasa Kure, Tomoya Tsukimi, Chiharu Ishii, et al.
World Journal of Urology|June 28, 2018
Surveillance after prostate focal therapyKae Jack Tay, Mahul B Amin, Sangeet Ghai, et al.
Clinical and Experimental Nephrology|January 26, 2015
Novel prediction model of renal function after nephrectomy from automated renal volumetry with preoperative multidetector computed tomography (MDCT)Shuji Isotani, Hirofumi Shimoyama, Isao Yokota, et al.
Pageof 13